Pulse Biosciences, Inc.

Pulse Biosciences, Inc. is a bioelectric medicine company headquartered in Hayward, California. The company is dedicated to advancing healthcare through its proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology, with a mission to improve and extend patients' lives by designing, producing, and commercializing nano-pulse technology.

The core of Pulse Biosciences' offerings is its nsPFA technology, which delivers nanosecond-duration electrical pulses to precisely ablate targeted cells non-thermally, while preserving surrounding non-cellular tissue. This technology is embodied in products such as the CellFX® System, initially commercialized for dermatologic conditions, and the nPulse System, which is being developed for soft tissue ablation, including applications in cardiac rhythm management for atrial fibrillation and the treatment of benign thyroid nodules. The company's strategy involves expanding beyond dermatology into larger hospital-based markets.

Led by CEO and Co-chairman Paul LaViolette, Pulse Biosciences has recently focused on strengthening its executive leadership, including the appointment of Liane Teplitsky as Chief Operating Officer in April 2026. Recent corporate activities include the planned redemption of warrants in June 2026 and presentations at major healthcare conferences. The company is actively progressing its clinical programs, notably initiating patient enrollment in the NANOPULSE-AF pivotal clinical study for atrial fibrillation and reporting positive data from its nPulse Cardiac Catheter System. Pulse Biosciences maintains a substantial intellectual property portfolio with over 130 global patents related to its nsPFA technology.